Rocket Doctor’s marketing agreement with Rick Ware Racing and FINTEKK AP is structured entirely in equity rather than cash. The company issued 7,000,000 common shares at a deemed price of US$0.50 each, worth a stated US$3.5 million, for services rendered from June 6 through September 30, paid out in monthly instalments as the campaign is completed.

If Rocket Doctor does not send notice to pause the arrangement at least ten days before September 30, services continue automatically through December 31 for an additional 3,000,000 shares at the same deemed price, worth US$1.5 million and issued in two tranches in November and December. A separate option, exercisable only with mutual written consent of all parties, would allow the marketing partners to receive up to US$5 million in additional shares for similar services in 2027.

Investor Yazan Al Homsi, a Rocket Doctor shareholder through Founders Round Capital, has pointed out that a deemed share price is not the same thing as a cash marketing budget or a guarantee of what those shares will be worth once issued, and that every tranche carries a lock-up restricting resale after issuance. He discloses his position directly and holds no operating role at the company; more of his analysis is on his website and his LinkedIn profile.

That structure means the true cost of the campaign to shareholders depends on where Rocket Doctor’s stock trades when each tranche is issued, not on the fixed dollar figures named in the agreement itself. The 2027 option, if exercised, would be a separate decision requiring mutual written consent from both sides rather than an automatic continuation.